Prognostic impact of achieving LDL cholesterol guidelines
Prognostic impact of achieving guideline-recommended LDL-C target in secondary prevention: A real-world study
This real-world study of PMI patients emphasizes the importance of achieving guideline-recommended secondary prevention goals of LDL-C <55 mg/dL and ≤50% from baseline to reduce Mace.
Main Takeaway
The incidence of Mace was 12.9% and 23.7% in the group attaining the 2019 goals (LDL-C <55 mg/dL) and in the group attaining 2016 goals (LDL-C <70 mg/dL), respectively.
Why This Matters
The 2019 ESC guidelines recommend a more ambitious target (to achieve LDL-C <55 mg/dL and to reduce it by ≥50% from baseline) than the previous guideline version (LDL-C <70 mg/dL or reduced ≥50% from baseline).
Data on the reduction of CV events in patients attaining the 2019 ESC goals are lacking in real-world population.
This study aimed to determine the risk of Mace during follow-up in PMI patients according to the achievement of the guideline-recommended goals in terms of LDL-C reduction.
Study Design
This was a retrospective analysis of a monocentric observational registry that prospectively enrolled patients hospitalized for ST segment elevation MI and followed-up in PMI ambulatory between January 2011 and February 2019.
Clinical and demographic data were extracted from digital database, and the clinical events that occurred during follow-up were obtained by telephone interviews or clinical records.
Endpoints: Mace defined as all-cause death, non-fatal MI, non-fatal stroke, and unplanned revascularization
LDL-C was collected at baseline and at 1, 6, and 12 months after the events. To define the achievement of target goals, the lower value was collected at follow-up.
Kaplan-Meier analysis and log-rank test were conducted for comparing patients who achieved LDL-C <55 mg/dL and ≤50% from baseline (group 2019) versus those who achieved LDL-C <70 mg/dL or ≤50% from baseline (group 2016).
Continuous variables are presented as medians (interquartile ranges).
Key Results
A total of 1,201 patients were included in the study (median age: 63 [54–72] years; female: 23%; hypertension: 56%; diabetes: 17%; smokers: 38%).
Baseline LDL-C was 123 (97–148) mg/dL; at follow-up, median LDL-C was 63 (52–78) mg/dL and was significantly reduced from baseline (P <0.0001).
Between 6 and 12 months, 83% of patients were treated with statins alone (73% with high intensity) and 17% with the addition of ezetimibe.
In total, 828 patients (69%) achieved the 2016 target, whereas 270 patients (22.5%) also achieved the 2019 target. Median follow-up was 60 (40–77) months.
Mace incidence was 12.9% and 23.7% in group 2019 and group 2016, respectively (HR = 0.61, 95% CI: 0.42–0.88; P log rank = 0.0087, number needed to treat = 9).
CI, confidence interval; CV, cardiovascular; ESC, European Society of Cardiology; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; MACE; major adverse cardiovascular event; MI, myocardial infarction; PMI, post myocardial infarction.
Casula M, Taietti I, Galazzi M, Zeqaj I, Fortuni F, Cornara S, et al. Prognostic impact of achieving LDL cholesterol guidelines-recommended target in secondary prevention: a real-world study. ePoster presented at the European Society of Cardiology (ESC) conference, August 27–30, 2021. [Abstract]34238023.10.1002/clc.23623. PMID: 34089263.
Related articles
Dyslipidemia
Cardiovascular
Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia
By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.